PPARA and obesity due to melanocortin 4 receptor deficiency: In addition, treatment with PPARα agonists in animal models of obesity attenuates adiposity and adipocyte hypertrophy and improves glucose metabolism defects, such as hyperglycemia, glucose intolerance and insulin resistance [2,8,9].